SCHEMBL32082017

SCHEMBL32082017

CCN1Cc2ccccc2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C19 P33261 1/20 0.55
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CARM1 Q86X55 1/20 0.46
CHRNA7 P36544 1/20 0.45
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
HSD17B3 P37058 1/20 0.43
NOTUM Q6P988 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
BACE1 P56817 1/20 0.42
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682960 1.00 ALDH1A1 (0.55) ALDH1A1CYP1A2CYP2D6CYP2C19NPC1
SCHEMBL153999 0.84 MAOA (0.57) ALDH1A1KDM4ECARM1MAOAMAOB
SCHEMBL31841937 0.84 MAOA (0.57) ALDH1A1KDM4ECARM1MAOAMAOB
SCHEMBL2632719 0.80 ALDH1A1 (0.68) ALDH1A1CYP1A2CYP2D6CYP2C19NPC1
SCHEMBL8391771 0.80 CYP3A4 (0.41) ALDH1A1CYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL7884784 0.78 CHRNA7 (0.50) ALDH1A1CYP1A2CYP2D6CYP2C19CHRNA7
SCHEMBL30072993 0.78 ALDH1A1 (0.59) ALDH1A1CYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL23848981 0.77 PRMT5 (0.42) ALDH1A1CYP1A2CYP2D6CYP2C19NPC1
SCHEMBL38660913 0.77 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL14670200 0.77 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260080976-A1 SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES PURDUE RESEARCH FOUNDATION (US) 2026-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260080976-A1 SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES BACE2, ADAM33, SET ALDH1A1 3785/4885CYP1A2 482/4885CYP2D6 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.